THALES - Acute STroke or Transient IscHaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death - THALES

Study identifier:D5134C00003

ClinicalTrials.gov identifier:NCT03354429

EudraCT identifier:2016-004232-37

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack

Medical condition

Acute Ischaemic Stroke, Transient ischaemic attack

Phase

Phase 3

Healthy volunteers

No

Study drug

Ticagrelor, Placebo

Sex

All

Actual Enrollment

11016

Study type

Interventional

Age

40 Years - 130 Years

Date

Study Start Date: 22 Jan 2018
Primary Completion Date: 13 Dec 2019
Study Completion Date: 13 Dec 2019

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2020 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria